{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:48:46Z","timestamp":1792097326940,"version":"4.4.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03392-6","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:04:40Z","timestamp":1789016680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers"],"prefix":"10.1007","volume":"43","author":[{"given":"Srijita","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8227-6005","authenticated-orcid":false,"given":"Swati","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Parveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"11","key":"3392_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828\u201351. https:\/\/doi.org\/10.1038\/nrd4389.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3392_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11\u201322. https:\/\/doi.org\/10.1038\/nrc969.","journal-title":"Nat Rev Cancer"},{"issue":"7781","key":"3392_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217\u201323. https:\/\/doi.org\/10.1038\/s41586-019-1694-1.","journal-title":"Nature"},{"issue":"1","key":"3392_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10(1):54\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1167.","journal-title":"Cancer Discov"},{"issue":"14","key":"3392_CR5","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Cancer Res. 2020;80(14):2969\u201374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3682.","journal-title":"Cancer Res"},{"key":"3392_CR6","unstructured":"KRAS G12D inhibitors.World Intellectual Property Organization. WO2021\/041671 A1. Mirati Therapeutics, Inc; Array Biopharma. 2021 4."},{"key":"3392_CR7","unstructured":"Applicant. Deuterated compounds useful as KRAS G12D inhibitors. World Intellectual Property Organization WO2022\/262838 A1. 2022 22."},{"key":"3392_CR8","unstructured":"Applicant. Macrocyclic RAS inhibitors. World Intellectual Property Organization WO2023\/240263 A1. 2023."},{"key":"3392_CR9","unstructured":"Mirati Therapeutics Inc. Combination therapies with KRAS G12D inhibitors and SOS1 inhibitors. World Intellectual Property Organization WO2023\/059597 A1. 2023."},{"key":"3392_CR10","unstructured":"Applicant. Pan-KRAS inhibitors (G12A\/C\/D\/R\/S\/V, G13D, Q61H). World Intellectual Property Organization WO2023\/244599 A1. 2023."},{"key":"3392_CR11","unstructured":"Applicant. KRAS(G12V) inhibitors. World Intellectual Property Organization. WO2024\/123913 A1. 2024."},{"key":"3392_CR12","unstructured":"Applicant. Farnesyltransferase inhibitors for treatment of KRAS-dependent cancers. World Intellectual Property Organization WO2024\/249551 A1. 2024 5."},{"issue":"7","key":"3392_CR13","doi-asserted-by":"publisher","first-page":"12501","DOI":"10.18632\/oncotarget.13915","volume":"8","author":"N Normanno","year":"2017","unstructured":"Normanno N, Denis MG, Thress KS, Ratcliffe M, Reck M. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget. 2017;8(7):12501\u201316. https:\/\/doi.org\/10.18632\/oncotarget.13915.","journal-title":"Oncotarget"},{"issue":"3","key":"3392_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","volume":"19","author":"LJ Jennings","year":"2017","unstructured":"Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, et al. Guidelines for validation of next-generation sequencing\u2013based oncology panels. J Mol Diagn. 2017;19(3):341\u201365. https:\/\/doi.org\/10.1016\/j.jmoldx.2017.01.011.","journal-title":"J Mol Diagn"},{"key":"3392_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224. https:\/\/doi.org\/10.1126\/scitranslmed.3007094.","journal-title":"Sci Transl Med"},{"issue":"7477","key":"3392_CR16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548\u201351. https:\/\/doi.org\/10.1038\/nature12796.","journal-title":"Nature"},{"issue":"7781","key":"3392_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217\u201323. https:\/\/doi.org\/10.1038\/s41586-019-1694-1.","journal-title":"Nature"},{"issue":"25","key":"3392_CR18","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2103695.","journal-title":"N Engl J Med"},{"issue":"2","key":"3392_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SHI, Pacheco JM, et al. Adagrasib in non\u2013small-cell lung cancer harboring a KRAS G12C mutation. N Engl J Med. 2022;387(2):120\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2204619.","journal-title":"N Engl J Med"},{"issue":"7","key":"3392_CR20","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS -mutant lung adenocarcinoma. Cancer Discov. 2018;8(7):822\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0099.","journal-title":"Cancer Discov"},{"issue":"25","key":"3392_CR21","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS G12C inhibition in cancer. N Engl J Med. 2021;384(25):2382\u201393. https:\/\/doi.org\/10.1056\/NEJMoa2105281.","journal-title":"N Engl J Med"},{"issue":"4","key":"3392_CR22","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.3390\/cimb45040213","volume":"45","author":"A \u015awi\u0119tek","year":"2023","unstructured":"\u015awi\u0119tek A, Go\u0142\u0105bek K, Hudy D, Ga\u017adzicka J, Biernacki K, Mi\u015bkiewicz-Orczyk K, et al. The potential association between E2F2, MDM2 and p16 protein concentration and selected sociodemographic and clinicopathological characteristics of patients with oral squamous cell carcinoma. Curr Issues Mol Biol. 2023;45(4):3268\u201378. https:\/\/doi.org\/10.3390\/cimb45040213.","journal-title":"Curr Issues Mol Biol"},{"key":"3392_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1380584","author":"H Miyashita","year":"2024","unstructured":"Miyashita H, Kato S, Hong DS. KRAS G12C inhibitor combination therapies: current evidence and challenge. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1380584.","journal-title":"Front Oncol"},{"key":"3392_CR24","unstructured":"OncLive. ASP3082 shows early efficacy in KRAS G12D\u2013mutant NSCLC with favorable safety profile. MJH Life Sciences 2024."},{"key":"3392_CR25","unstructured":"Reddit. Patient and researcher discussion on RMC-6236 and RMC-9805 combination trials. 2024."},{"key":"3392_CR26","unstructured":"PubMed. Clinical activity of VS-6766 in KRAS-mutant cancers. . US National Library of Medicine. 2022."},{"key":"3392_CR27","unstructured":"NCBI. Targeting SOS1\u2013KRAS interaction: preclinical rationale for combination strategies. . National Center for Biotechnology Information. 2023."},{"key":"3392_CR28","unstructured":"Mirati Therapeutics. Oncology pipeline [Webpage]. Mirati Therapeutics. 2024."},{"key":"3392_CR29","unstructured":"Eli Lilly and Company. https:\/\/clinicaltrials.gov\/study\/NCT06099999. ClinicalTrials.gov US National Library of Medicine. 2023."},{"key":"3392_CR30","unstructured":"Bayer AG. Bayer and Kumquat announce global license agreement for KRAS G12D inhibitor KBQ548 valued up to $1.3 billion [Press release]. GlobeNewswire. 2025"},{"key":"3392_CR31","unstructured":"Kobayashi S, BE, & YK. Targeting KRAS mutations with next-generation inhibitors: Progress and challenges. Cancer Discovery, 14(8), 1234\u20131245 . 2024."},{"key":"3392_CR32","unstructured":"Bayer AG. Bayer and Kumquat announce global license agreement for KRAS G12D inhibitor KBQ548 valued up to $1.3 billion [Press release]. PR Newswire. 2025."},{"key":"3392_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107886","volume":"194","author":"Y Oya","year":"2024","unstructured":"Oya Y, Imaizumi K, Mitsudomi T. The next-generation KRAS inhibitors\u2026What comes after sotorasib and adagrasib? Lung Cancer. 2024;194:107886. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107886.","journal-title":"Lung Cancer"},{"key":"3392_CR34","unstructured":"Daily Reporter. Promising antitumour activity presented for emerging targets in different solid tumours. Daily Reporter\u2014ESMO Congress coverage. 2024"},{"key":"3392_CR35","unstructured":"Verastem. Verastem Oncology exercises option for global rights (outside China) to GenFleet\u2019s KRAS-G12D inhibitor GFH375 (VS-7375) [Press release]. Verastem Oncology. 2025."},{"key":"3392_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.lungcan.2019.01.003","volume":"130","author":"L La Fleur","year":"2019","unstructured":"La Fleur L, Falk-S\u00f6rqvist E, Smeds P, Berglund A, Sundstr\u00f6m M, Mattsson JS, et al. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer. 2019;130:50\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2019.01.003.","journal-title":"Lung Cancer"},{"issue":"2","key":"3392_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","volume":"11","author":"T Isermann","year":"2025","unstructured":"Isermann T, Sers C, Der CJ, Papke B. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends Cancer. 2025;11(2):91\u2013116. https:\/\/doi.org\/10.1016\/j.trecan.2024.11.009.","journal-title":"Trends Cancer"},{"issue":"18","key":"3392_CR38","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1200\/JCO.22.02524","volume":"41","author":"GK Dy","year":"2023","unstructured":"Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non\u2013small-cell lung cancer: 2-year analysis of CodeBreaK 100. J Clin Oncol. 2023;41(18):3311\u20137. https:\/\/doi.org\/10.1200\/JCO.22.02524.","journal-title":"J Clin Oncol"},{"issue":"25","key":"3392_CR39","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2103695.","journal-title":"N Engl J Med"},{"issue":"7","key":"3392_CR40","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","volume":"13","author":"MV Negrao","year":"2023","unstructured":"Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, et al. Comutations and KRASG12C inhibitor efficacy in advanced NSCLC. Cancer Discov. 2023;13(7):1556\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1420.","journal-title":"Cancer Discov"},{"issue":"5","key":"3392_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051321","volume":"14","author":"D Reita","year":"2022","unstructured":"Reita D, Pabst L, Pencreach E, Gu\u00e9rin E, Dano L, Rimelen V, et al. Direct targeting KRAS mutation in non-small cell lung cancer: focus on resistance. Cancers (Basel). 2022;14(5):1321. https:\/\/doi.org\/10.3390\/cancers14051321.","journal-title":"Cancers (Basel)"},{"key":"3392_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1328728","author":"A Chour","year":"2024","unstructured":"Chour A, Toffart AC, Berton E, Duruisseaux M. Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1328728.","journal-title":"Front Oncol"},{"issue":"12","key":"3392_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan MB, Coker O, Sorokin A, Fella K, Barnes H, Wong E, et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 2022;39(12):110993. https:\/\/doi.org\/10.1016\/j.celrep.2022.110993.","journal-title":"Cell Rep"},{"issue":"2","key":"3392_CR44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrc.2017.118","volume":"18","author":"T Brabletz","year":"2018","unstructured":"Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18(2):128\u201334. https:\/\/doi.org\/10.1038\/nrc.2017.118.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"3392_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611\u201329. https:\/\/doi.org\/10.1038\/nrclinonc.2017.44.","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"3392_CR46","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","volume":"26","author":"Y Adachi","year":"2020","unstructured":"Adachi Y, Ito K, Hayashi Y, Kimura R, Tan TZ, Yamaguchi R, et al. Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C\u2013mutant non\u2013small cell lung cancer. Clin Cancer Res. 2020;26(22):5962\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2077.","journal-title":"Clin Cancer Res"},{"key":"3392_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1004669","author":"W Ning","year":"2022","unstructured":"Ning W, Marti TM, Dorn P, Peng RW. Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.1004669.","journal-title":"Front Oncol"},{"issue":"9","key":"3392_CR48","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1158\/1078-0432.CCR-20-3872","volume":"27","author":"HS Solanki","year":"2021","unstructured":"Solanki HS, Welsh EA, Fang B, Izumi V, Darville L, Stone B, et al. Cell type\u2013specific adaptive signaling responses to KRASG12C inhibition. Clin Cancer Res. 2021;27(9):2533\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3872.","journal-title":"Clin Cancer Res"},{"issue":"5340","key":"3392_CR49","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","volume":"278","author":"LH Hartwell","year":"1997","unstructured":"HartwellLH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Sci (1979). 1997;278(5340):1064\u20138. https:\/\/doi.org\/10.1126\/science.278.5340.1064.","journal-title":"Sci (1979)"},{"issue":"3","key":"3392_CR50","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","volume":"42","author":"X Tong","year":"2024","unstructured":"Tong X, Patel AS, Kim E, Li H, Chen Y, Li S, et al. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer. Cancer Cell. 2024;42(3):413-428.e7. https:\/\/doi.org\/10.1016\/j.ccell.2024.01.012.","journal-title":"Cancer Cell"},{"issue":"23","key":"3392_CR51","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;389(23):2125\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2308795.","journal-title":"N Engl J Med"},{"issue":"1","key":"3392_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SHI, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;388(1):44\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2212419.","journal-title":"N Engl J Med"},{"issue":"1","key":"3392_CR53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","volume":"30","author":"J Desai","year":"2024","unstructured":"Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, et al. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024;30(1):271\u20138. https:\/\/doi.org\/10.1038\/s41591-023-02696-8.","journal-title":"Nat Med"},{"issue":"22","key":"3392_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225384","volume":"15","author":"A Tojjari","year":"2023","unstructured":"Tojjari A, Saeed A, Sadeghipour A, Kurzrock R, Cavalcante L. Overcoming immune checkpoint therapy resistance with SHP2 inhibition in cancer and immune cells: a review of the literature and novel combinatorial approaches. Cancers (Basel). 2023;15(22):5384. https:\/\/doi.org\/10.3390\/cancers15225384.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"3392_CR55","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","volume":"8","author":"C Fedele","year":"2018","unstructured":"Fedele C, Ran H, Diskin B, Wei W, Jen J, Geer MJ, et al. SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models. Cancer Discov. 2018;8(10):1237\u201349. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0444.","journal-title":"Cancer Discov"},{"issue":"1","key":"3392_CR56","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/14796694.2024.2430172","volume":"21","author":"JP Higgins","year":"2025","unstructured":"Higgins JP, Carlisle JW, Moniri NH, Gupta S, Oduah EI, Leal T. Sotorasib for the treatment of locally advanced\/metastatic non-small cell lung cancer. Future Oncol. 2025;21(1):63\u201371. https:\/\/doi.org\/10.1080\/14796694.2024.2430172.","journal-title":"Future Oncol"},{"key":"3392_CR57","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2441499","author":"Q He","year":"2025","unstructured":"He Q, Liu X, Jiang L, Liu P, Xuan W, Wang Y, et al. First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives. Cancer Biol Ther. 2025. https:\/\/doi.org\/10.1080\/15384047.2024.2441499.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"3392_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9305","volume":"6","author":"S Misale","year":"2015","unstructured":"Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nat Commun. 2015;6(1):8305. https:\/\/doi.org\/10.1038\/ncomms9305.","journal-title":"Nat Commun"},{"issue":"1","key":"3392_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","volume":"83","author":"CM Goodwin","year":"2023","unstructured":"Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, et al. Combination therapies with CDK4\/6 inhibitors to treat KRAS- mutant pancreatic cancer. Cancer Res. 2023;83(1):141\u201357. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0391.","journal-title":"Cancer Res"},{"issue":"10","key":"3392_CR60","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 2022;28(10):2171\u201382. https:\/\/doi.org\/10.1038\/s41591-022-02007-7.","journal-title":"Nat Med"},{"issue":"6","key":"3392_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061204","volume":"13","author":"LM Mustachio","year":"2021","unstructured":"Mustachio LM, Chelariu-Raicu A, Szekvolgyi L, Roszik J. Targeting KRAS in cancer: promising therapeutic strategies. Cancers (Basel). 2021;13(6):1204. https:\/\/doi.org\/10.3390\/cancers13061204.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"3392_CR62","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031435","volume":"8","author":"AM Waters","year":"2018","unstructured":"Waters AM, Der CJ. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med. 2018;8(9):a031435. https:\/\/doi.org\/10.1101\/cshperspect.a031435.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"3392_CR63","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828\u201351. https:\/\/doi.org\/10.1038\/nrd4389.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"3392_CR64","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14","author":"G Siravegna","year":"2017","unstructured":"Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531\u201348. https:\/\/doi.org\/10.1038\/nrclinonc.2017.14.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"3392_CR65","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","volume":"25","author":"AR Parikh","year":"2019","unstructured":"Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019;25(9):1415\u201321. https:\/\/doi.org\/10.1038\/s41591-019-0561-9.","journal-title":"Nat Med"},{"issue":"4","key":"3392_CR66","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338. https:\/\/doi.org\/10.1038\/nrc.2017.7.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"3392_CR67","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","volume":"13","author":"C Rolfo","year":"2018","unstructured":"Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018;13(9):1248\u201368. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.030.","journal-title":"J Thorac Oncol"},{"issue":"25","key":"3392_CR68","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS G12C inhibition in cancer. N Engl J Med. 2021;384(25):2382\u201393. https:\/\/doi.org\/10.1056\/NEJMoa2105281.","journal-title":"N Engl J Med"},{"issue":"12","key":"3392_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan MB, Coker O, Sorokin A, Fella K, Barnes H, Wong E, et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 2022;39(12):110993. https:\/\/doi.org\/10.1016\/j.celrep.2022.110993.","journal-title":"Cell Rep"},{"issue":"2","key":"3392_CR70","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/annonc\/mdy509","volume":"30","author":"CM Parseghian","year":"2019","unstructured":"Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30(2):243\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdy509.","journal-title":"Ann Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03392-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03392-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03392-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:41:32Z","timestamp":1792096892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03392-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":70,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3392"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03392-6","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author confirms that there is no conflict of interest in the content.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"277"}}